Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAAV-shRNA targeting MRGN
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
rAAV-shRNA targeting MRGN is an experimental gene therapy developed by the University of Florida and Lacerta Therapeutics for the treatment of glioblastoma (GBM). The therapy utilizes a novel recombinant adeno-associated virus (rAAV) capsid, identified through AI-directed screening for high tropism to GBM cells, to deliver short hairpin RNA (shRNA) cassettes. These shRNAs are designed to target and deconstruct the Master Regulatory Gene Network (MRGN), a common regulatory state found in GBM stem-like cells (GSCs) that drives tumor heterogeneity and growth. By silencing key master regulators within this network, the therapy aims to attenuate tumor growth and improve survival in a heterogeneity-agnostic manner.
- Other names
- AAV-shRNA targeting MRGN
02
Targets
AAVR (AAV receptor)Endogenous RNA interference and microRNA machineryMRGN (Master Regulatory Gene Network)
Beyond the preview
Go deeper on rAAV-shRNA targeting MRGN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rAAV-shRNA targeting MRGN.